A molecular docking study of potential inhibitors and repurposed drugs against SARS-CoV-2 main protease enzyme

• Published in: Journal of the Indian Chemical Society Vol. 98; no. 3; p. 100041
• Main Authors: Ercan, Selami, Çınar, Ercan
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.03.2021; Indian Chemical Society. Published by Elsevier B.V
• Subjects: Autodock4; COVID-19; Main protease; Molecular docking; Sars-CoV-2; COVID-19; Autodock4; Main protease; Molecular docking; Sars-CoV-2
• ISSN: 0019-4522; 0019-4522
• DOI: 10.1016/j.jics.2021.100041

COVID-19 has affected millions of people. Although many drugs are in use to combat disease, there is not any sufficient treatment yet. Having critical role in propagation of the novel coronavirus (SARS-CoV-2) works Main Protease up into a significant drug target. We have performed a molecular docking study to define possible inhibitor candidates against SARS-CoV-2 Main Protease enzyme. Besides docking Remdesivir, Ribavirin, Chloroquine and 28 other antiviral inhibitors (totally 31 inhibitors) to Main Protease enzyme, we have also performed a molecular docking study of 2177 ligands, which are used against Main Protease for the first time by using molecular docking program Autodock4. All ligands were successfully docked into Main Protease enzyme binding site. Among all ligands, EY16 coded ligand which previously used as EBNA1-DNA binding blocker candidate showed the best score for Main Protease with a binding free energy of −10.83 ​kcal/mol which was also lower than re-docking score of N3 ligand (−10.72 ​kcal/mol) contained in crystal structure of Main Protease. After analyzing the docking modes and docking scores we have found that our ligands have better binding free energy values than the inhibitors in use of treatment. We believe that further studies such as molecular dynamics or Molecular Mechanic Poisson Boltzmann Surface Area studies can make contribution that is more exhaustive to the docking results. [Display omitted] •2208 ligands were successfully placed to binding site of SARS-COV-2 Mpro.•Ligand EY16 binds as the best of used ligands to the Mpro.•EY16, EZ055, EZ0239, HB393, HB099, HB110 and HMZ24 ligands could be considered as inhibitor candidates for Mpro.